⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 3, 2024

Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Robert W. Lentz Tyler J. Friedrich Patrick J. Blatchford Kimberly R. Jordan Todd M. Pitts Hannah R. Robinson S. Lindsey Davis Sunnie S. Kim Alexis D. Leal Mathew R. Lee Meredith R.N. Waring Anne C. Martin Adrian T.A. Dominguez Stacey M. Bagby Sarah J. Hartman S. Gail Eckhardt Wells A. Messersmith Christopher H. Lieu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S7. Correlation of baseline immune cell populations with response to treatment in Cohorts A and B.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lentz et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db643587533992 https://doi.org/10.1158/1078-0432.26925996.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024
2Supplementary Figure S8 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024
3Supplementary Figure S8 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024
4Supplementary Figure S6 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024
5Supplementary Figure S6 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024